​Daniel D. Von Hoff, M.D., is physician-in-chief and director of translational research at TGen (Translational Genomics Research Institute) in Phoenix, Ariz.; chief scientific officer for US Oncology and for Scottsdale Healthcare Clinical Research Institute and clinical professor of medicine at the University of Arizona.

Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He completed his internship and residency at the University of California, San Francisco, and a fellowship at the National Cancer Institute. Von Hoff became a professor in the departments of medicine and cellular and structural biology at the University of Texas Health Science Center, San Antonio. In 1989, he became the founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio and later became director of the cancer center and professor of medicine at the University of Arizona.

Von Hoff’s major interest is in the development of new anticancer agents. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely. At present, Von Hoff’s work concentrates on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.

He is currently serving a six-year term on the National Cancer Advisory Board and has served on the FDA’s Oncology Advisory Committee. Von Hoff is a past president of the American Association for Cancer Research, was on the AACR and the American Society of Clinical Oncology’s Board of Directors, and is a fellow of the American College of Physicians. Von Hoff is the founder of Investigational New Drugs - The Journal of New Anticancer Agents and is editor-in-chief of Molecular Cancer Therapeutics. He was the associate editor for two AACR journals, Clinical Cancer Research and Cancer Research.